Clinical trial
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
NCT00003590 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00003590 |
|---|---|
| Title | S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma |
| Official title | Phase II Study of Hydroxyurea for Unresectable Meningioma |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH Eastern Cooperative Oncology Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Meningioma |
| Intervention type | Drug |
| Interventions | hydroxyurea |
| Enrollment | 29 |
| Start date | Nov 1, 1998 |
| Primary completion | Dec 1, 2008 |
| Completion | Jul 1, 2011 |
| First posted | Jan 27, 2003 |
| Last update posted | May 20, 2016 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: